32 related articles for article (PubMed ID: 15130414)
1. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
3. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET and PET/CT in Burkitt's lymphoma.
Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA
Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248
[TBL] [Abstract][Full Text] [Related]
7. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
9. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma.
Haerle SK; Strobel K; Hany TF; Sidler D; Stoeckli SJ
Head Neck; 2010 Mar; 32(3):319-25. PubMed ID: 19626642
[TBL] [Abstract][Full Text] [Related]
10. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration].
Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490
[TBL] [Abstract][Full Text] [Related]
12. Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma.
Even-Sapir E; Lerman H; Figer A; Rabau M; Livshitz G; Inbar M; Gutman M
J Nucl Med; 2002 May; 43(5):603-9. PubMed ID: 11994521
[TBL] [Abstract][Full Text] [Related]
13. Beta-2 microglobulin as a diagnostic parameter in non-Hodgkin lymphoma: a comparative study with FDG-PET.
Toth DF; Raderer M; Wadsak W; Karanikas G
Anticancer Res; 2013 Aug; 33(8):3341-5. PubMed ID: 23898101
[TBL] [Abstract][Full Text] [Related]
14. Elucidation of acute renal failure due to recurrent non-Hodgkin lymphoma by F-18 FDG PET/CT.
Rozalli FI; Chua SC; Green DJ
Clin Nucl Med; 2008 Mar; 33(3):201-3. PubMed ID: 18287847
[No Abstract] [Full Text] [Related]
15. Hypermetabolic change as a possible predictive sign of a relapsed central nervous system lymphoma.
Nakahara T; Takagi Y; Shiga H; Uchida H; Kaburaki J; Kubo A
Clin Nucl Med; 2007 Feb; 32(2):87-9. PubMed ID: 17242558
[TBL] [Abstract][Full Text] [Related]
16. Normal and Abnormal Patterns of (18)F-Fluorodeoxyglucose PET/CT in Lymphoma.
Bar-Shalom R
PET Clin; 2006 Jul; 1(3):231-42. PubMed ID: 27157362
[No Abstract] [Full Text] [Related]
17. PET Assessment of Lymphoma: Beyond (18)F-Fluorodeoxyglucose.
Reske S
PET Clin; 2006 Jul; 1(3):275-81. PubMed ID: 27157366
[No Abstract] [Full Text] [Related]
18. Is
Barrington SF; Cottereau AS; Zijlstra JM
J Nucl Med; 2024 Feb; 65(4):510-1. PubMed ID: 38388515
[No Abstract] [Full Text] [Related]
19. [The clinical application of 18F-fluorodeoxyglucose coincidence imaging in lymphoma].
Wang RF; Zhang XM; Zhang CL; Fu ZL; Fan Y; Cen XN
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):284-7. PubMed ID: 15130414
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
